Lorcaserin in the Treatment of Cocaine Use Disorder
Launched by NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) · Dec 28, 2016
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
This is a 19-week, multi-center, randomized, Phase 2 clinical study comparing the efficacy of lorcaserin (10mg, b.i.d) to matched placebo in the treatment of cocaine use disorder. Up to 3 weeks will be allowed for the Screening Period and a 13-week treatment phase, with a 3-week follow-up period, with scheduled visits during Study weeks 14 and 16.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Has a DSM-5 diagnosis of current cocaine use disorder as verified by the Structured Clinical Interview for DSM-5
- • Is seeking treatment for cocaine use disorder
- • Is able to understand and provide written informed consent
- • Has used cocaine on at least 1 day in the last 30 days prior to screening
- • Has completed all psychological assessments and procedures during the screening period
- • If female, not pregnant, lactating, unable to conceive OR must agree to use an acceptable method of birth control
- • Has a total body weight greater than 110 pounds and body mass index greater than 20
- Exclusion Criteria:
- • Contact site for more information
About National Institute On Drug Abuse (Nida)
The National Institute on Drug Abuse (NIDA) is a leading federal agency within the U.S. Department of Health and Human Services, dedicated to advancing the understanding of drug abuse and addiction through rigorous scientific research. NIDA's mission encompasses the exploration of the biological, behavioral, and social aspects of substance use disorders, facilitating the development of effective prevention and treatment strategies. By funding and conducting innovative clinical trials, NIDA aims to translate research findings into practical solutions that improve public health and inform policy, ultimately contributing to the reduction of substance-related harm in communities across the nation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Los Angeles, California, United States
Cincinnati, Ohio, United States
Las Vegas, Nevada, United States
Portland, Oregon, United States
Lakeland, Florida, United States
Newport Beach, California, United States
North Miami, Florida, United States
Berlin, New Jersey, United States
La Jolla, California, United States
Boston, Massachusetts, United States
Canton, Ohio, United States
Patients applied
Trial Officials
Shwe Gyaw, MD
Study Chair
National Institute on Drug Abuse (NIDA)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials